Cash Equivalents and Marketable Securities: $245 million as of December 31, 2024, down from $314 million as of December 31, 2023. R&D Expenses: $209 million for the year ended December 31, 2024, compared to $232 million in 2023. Net Proceeds from Public Offering: $131 million received from an upsized public offering of common stock and
Cash, Cash Equivalents, and Marketable Securities: $134.6 million at the end of 2024. Net Cash Used in Operating Activities: $19.3 million for Q4 2024, down from $32 million in Q4 2023. Collaboration Revenue: $16.4 million for Q4 2024, up from $10.7 million in Q4 2023. Research & Development Expenses: $22.3 million for Q4 2024, compared
Revenue (Q4 2024): $400,000 from future astronaut membership fees. Total Operating Expenses (Q4 2024): $82 million, down from $117 million in the prior year period. Adjusted EBITDA (Q4 2024): Negative $63 million, improved from negative $84 million in the prior year period. Free Cash Flow (Q4 2024): Negative $117 million. Revenue (Full Year 2024): $7
GH Research PLC Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025 Phase 1 clinical trial to evaluate proprietary aerosol delivery device in healthy volunteers is ongoing in the UK Full response to the IND hold on track
Total Revenue (2024): $560 million, representing 29% growth over 2023. Crysvita Revenue (2024): $410 million, with 25% growth over 2023. Dojolvi Revenue (2024): $88 million, representing 25% growth over 2023. Evkeeza Revenue (2024): $32 million. Mepsevii Revenue (2024): $30 million. Total Operating Expenses (2024): $1.1 billion. R&D Expenses (2024): $698 million. SG&A Expenses (2024): $322
Cash and Marketable Securities: Over $1.4 billion as of year-end 2024. Cash Burn: Approximately $191 million in Q4 2024. Global Net Revenue 2024: $363.7 million, reflecting 19% year-over-year growth. US Net Revenue 2024: $254.8 million, up 14% compared to 2023. Japan Net Revenue 2024: $87.7 million, up 33% compared to 2023. Europe and Rest of
Revenue: $148 million, up 4% year-over-year on an organic basis. Non-GAAP EPS: $0.08 per share. Adjusted EBITDA Margin: 9%, representing a 400 basis point expansion year-over-year. Free Cash Flow: $2 million for the quarter. Cash Position: $530 million in cash, cash equivalents, and marketable securities. Sample Management Solutions Revenue: $81 million, up 3% year-over-year. Multiomics
Cargo Therapeutics, Inc. CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a competitive benefit-risk profile for patients. CARGO to implement a workforce reduction of approximately 50%. Phase 1 dose escalation study enrollment for CRG-023 on track to initiate in Q2 2025. SAN CARLOS,
What is Nasdaq Cash, Cash Equivalents, Marketable Securities? Nasdaq‘s quarterly cash, cash equivalents, marketable securities declined from Dec. 2023 ($641.00 Mil) to Mar. 2024 ($561.00 Mil) but then increased from Mar. 2024 ($561.00 Mil) to Jun. 2024 ($590.00 Mil). Nasdaq‘s annual cash, cash equivalents, marketable securities increased from Dec. 2021 ($601.00 Mil) to Dec. 2022
What is Altice USA Cash, Cash Equivalents, Marketable Securities? Altice USA‘s quarterly cash, cash equivalents, marketable securities declined from Dec. 2023 (MXN5,127.21 Mil) to Mar. 2024 (MXN4,720.81 Mil) but then increased from Mar. 2024 (MXN4,720.81 Mil) to Jun. 2024 (MXN6,633.84 Mil). Altice USA‘s annual cash, cash equivalents, marketable securities increased from Dec. 2021 (MXN4,014.82 Mil)